Interruption of nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B – A new concept to achieve HBsAg decline?
C Höner zu Siederdissen, K Deterding, K Port, B Maasoumy, AA Markova, MP Michael, H Wedemeyer, M Cornberg · Zeitschrift für Gastroenterologie · 2015 · Heft 01
Bibliografische Angaben
Zusammenfassung
Background: Effective suppression of HBV DNA with nucleoside or nucleotide analogues (NA) has shown to delay disease progression in patients with chronic hepatitis B. However, HBsAg loss during NA treatment is a rare event. Thus, treatment duration with NA is not finite and stopping rules before HBsAg loss are not clearly defined, especially in HBeAg negative patients. Methods: We prospectively stopped NA treatment in patients with HBeAg negative chronic hepatitis B. Inclusion criteria were ongoing antiviral treatment with NA and suppressed HBV DNA < 20 IU/ml for at least 3 years as well as HBsAg < 3500 IU/ml. P…
